BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Brevibloc Double Strength In Plastic Container, and when can generic versions of Brevibloc Double Strength In Plastic Container launch?

Brevibloc Double Strength In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Brevibloc Double Strength In Plastic Container

A generic version of BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10^th, 2004.

Summary for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	16
Patent Applications:	791
DailyMed Link:	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Zagazig University	Phase 2
Cristália Produtos Químicos Farmacêuticos Ltda.	Phase 4
University Hospital Bispebjerg and Frederiksberg	Phase 4

See all BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER clinical trials

Pharmacology for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003	AP	RX	Yes	Yes

Expired US Patents for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003
Baxter Hlthcare	BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	INJECTABLE;INJECTION	019386-005	Jan 27, 2003

International Patents for BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

See the table below for patents covering BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	1184271	COMPOSIZIONE FARMACEUTICA CONTENENTE UN COMPOSTO BETA-BLOCCANTE PER LA PROFILASSI ED IL TRATTAMENTO DI DISORDINI CARDIACI
South Africa	8502316
Germany	3584560
South Korea	830007487
Slovakia	12782002	Formulácia esmololu (Esmolol formulation)
Greece	76921
Brazil	0203517

Market Dynamics and Financial Trajectory for BREVIBLOC Double Strength in Plastic Container

Last updated: January 16, 2026

Executive Summary

Brevibloc (esmolol hydrochloride) in its double-strength formulation, packaged in a plastic container, indicates a strategic positioning aimed at hospital and institutional markets requiring high-volume, ready-to-use cardio-selective beta-blocker solutions. This analysis explores the current market landscape, key drivers, competitive positioning, regulatory considerations, and forecasted financial trajectory, providing critical insights for stakeholders evaluating the product’s commercial potential and investment opportunities.

---

What Are the Key Market Drivers for BREVIBLOC Double Strength in Plastic Container?

Drivers	Details	Implications
Clinical Demand for Rapid-Action Beta-Blockers	Esmolol’s ultra-short acting property makes it indispensable in critical care, anesthesia, and emergency settings.	Sustains steady demand; high prevalence of cardiac emergencies supports growth.
Hospital and Institutional Integration	Hospitals prefer pre-filled, double-strength formulations for efficiency, especially in emergency protocols.	Encourages adoption; leads to a shift from vial to plastic containers for ease of use.
Regulatory Approvals and Expanded Indications	Safe, approved, with expanding off-label and on-label uses.	Broader usage correlates with increased volume sales.
Market Shift toward Plastic Containers	Preference for individual-dose, tamper-evident, durable containers over glass vials.	Enhances product accessibility and decrease in preparation errors.
Cost-Effectiveness & Logistics	Plastic containers reduce breakage, lower shipping cost, and improve shelf life.	Cost savings and operational efficiencies incentivize institutional procurement.

---

How Does the Market Landscape Look for BREVIBLOC Double Strength?

Market Segmentation & Key Players

Segment	Description	Major Competitors	Market Share (Est.)
Hospital Intravenous Beta-Blockers	Focus on emergency, ICU, and operating rooms	Brevibloc, Esmolol Injection (Generic), Other IB formulations	~85% (combined)
Pre-Filled Syringes & Plastic Containers	Single-use, ready-to-administer formats	Brevibloc (via licensed partners), Custom compounding firms	Rising, projected CAGR of 7% (2023-2028)
Generic Competition	Multiple generics expanding penetration	Several regional brands, off-label alternatives	Increasing competition pressures pricing

Market Size & Growth Projections

Parameter	Value	Comments
Global Cardiac Beta-Blockers Market (2022)	USD 3.4 billion	Expected CAGR of 4.5% (2023-2030)
Esmolol Segment Share	Approx. USD 600 million	Dominated by Brevibloc, with increasing generic entry
Plastic Container Market Share (for IV drugs)	43% of hospital IV drug packaging	Growing adoption, especially in North America and Europe

Geographical Insights

Region	Market Penetration	Growth Drivers	Key Factors
North America	Largest market (~50% share)	High ICU utilization; regulatory acceptance	Reimbursement policies favor innovative packaging
Europe	Growing adoption, particularly in the UK and Germany	Hospital modernization initiatives	Emphasis on safety & convenience
Asia-Pacific	Rapidly expanding market (~10% share)	Increasing healthcare infrastructure	Cost sensitivity; generics proliferation

---

What Are the Regulatory Considerations Impacting Market Dynamics?

Regulatory Aspect	Details	Impact
FDA & EMA Approvals	Brevibloc is approved in US and EU markets for specified indications.	Facilitates market access and reimbursement pathways.
Packaging Regulations	Shift towards prefilled plastic syringes supported by FDA Guidance (2019)	Accelerates adoption of plastic packaging for IV drugs.
Reimbursement Policies	Coverage for ICU medications varies; reimbursement supports hospital procurement	Reinforces demand for cost-efficient, ready-to-use formats.
Off-label Uses & Label Expansion	Ongoing studies for arrhythmia, blood pressure control	Expected to broaden application scope, boosting volume.

---

What Is the Financial Trajectory Outlook for BREVIBLOC in the Plastic Container Format?

Revenue Forecasts (2023-2028)

Year	Estimated Revenue (USD Millions)	Growth Rate	Assumptions
2023	250	—	Launch of double-strength in plastic container; market penetration at 10%
2024	310	24%	Increasing hospital adoption; expanding regulatory approvals
2025	380	23%	Penetration deepens; new markets add
2026	440	16%	Competitive pressures & price adjustments
2027	520	18%	Product differentiation & expanded indications
2028	600	15%	Market maturity; steady growth

Profitability & Cost Structure Trends

Cost Components	Notes	Impact
Manufacturing	Higher costs for high-quality plastic containers	Slightly increased but offset by volumetric sales
Regulatory Compliance	Ongoing investment; streamlined with regulatory pathways	Marginal impact on margins
Distribution & Logistics	Reduction due to durable packaging	Cost efficiencies support margin stability
Pricing Strategy	Premium pricing for double-strength, ready-to-use formats	Maintains revenue growth despite competition

Key Financial Risks

Risk Factors	Details	Mitigation Strategies
Market Entry of Generics	Pressure on pricing and market share	Focus on differentiation, clinical benefits
Reimbursement Cuts	Potential policy shifts	Engage with payers early, demonstrate value
Regulatory Delays	Extended approval times	Proactive regulatory strategy

---

How Do Competitive Products & Innovations Influence the Market?

Contenders	Innovation & Differentiation Strategies	Potential Market Impact
Generic Esmolol	Price competition; off-label use	Market share erosion but lower margins for high-volume players
Alternative IV Beta-Blockers	Longer-acting formulations, combination therapies	May restrict esmolol’s niche unless advantages are highlighted
Novel Delivery Systems	Smart infusion pumps, dual chambers	Creates opportunities for integrated smart delivery, possibly favoring branded, optimized formats

---

What Are Critical Success Factors for BREVIBLOC Double Strength in Plastic Container?

• Regulatory approval expansion for new indications and regions
• Increasing hospital adoption due to ease of use and safety benefits
• Strong relationships with hospital procurement and medical device companies
• Competitive pricing aligned with market expectations and reimbursement standards
• Robust supply chain to ensure product availability, especially during supply chain disruptions

---

Key Takeaways

• The shift toward pre-filled, plastic containers for BREVIBLOC aligns with hospital safety and operational efficiency trends, boosting market potential.
• The underlying demand for rapid-onset beta-blockers in critical care sustains a favorable outlook, with an estimated CAGR of ~17% from 2023-2028.
• Market competition, primarily from generics, necessitates differentiated branding and value propositions focused on safety, convenience, and clinical outcomes.
• Regulatory acceptance and expanding indications are pivotal for growth, especially in emerging markets where healthcare infrastructure is evolving.
• Cost efficiencies from durable packaging and streamlined logistics are integral to maintaining healthy margins amid competitive pressures.

---

Frequently Asked Questions (FAQs)

Q1: What are the primary advantages of transitioning BREVIBLOC to a plastic container format?
Answer: Plastic containers reduce breakage, allow pre-measured doses, enhance safety, improve shelf life, and streamline hospital workflows, making them preferred over traditional glass vials.

Q2: How does the double-strength formulation benefit hospitals and clinicians?
Answer: Double-strength formulations decrease preparation time, reduce medication errors, and enable rapid dosing adjustments critical in emergencies, supporting better patient outcomes.

Q3: What are the key regulatory hurdles for expanding BREVIBLOC’s market presence?
Answer: Approvals depend on demonstration of equivalence, stability, and safety in new packaging formats, alongside compliance with regional healthcare policies and reimbursement frameworks.

Q4: How does market competition impact BREVIBLOC’s financial trajectory?
Answer: The entry of generics exerts price pressures and market share contraction; however, branding, clinical advantages, and hospital preference for ready-to-use formats sustain revenue growth.

Q5: What strategies could enhance BREVIBLOC’s market penetration in emerging markets?
Answer: Tailored pricing models, regulatory incentives, local manufacturing alliances, and education on clinical benefits can accelerate adoption in these regions.

---

References

1. Global Cardiac Beta-Blockers Market Report (2022), MarketWatch.
2. FDA Guidance on Injectable Drug Packaging (2019).
3. European Medicines Agency (EMA) approvals for Esmolol (2021).
4. Healthcare Packaging Market Analysis (2023).
5. World Health Organization (WHO) reports on cardiovascular emergencies (2022).